(MENAFN- GlobeNewsWire - Nasdaq) Bioconjugation Reagents Market to Reach $3.87 Billion by 2030 as Precision Medicine and Antibody-Drug Conjugate Demand ExpandsDublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Bioconjugation Reagents Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The global bioconjugation reagents market is experiencing strong growth, supported by rising pharmaceutical and biotechnology research and development, expanding diagnostic and molecular imaging applications, and increased investment in proteomics and genomics. The market is projected to grow from $2.52 billion in 2025 to $2.74 billion in 2026, representing a compound annual growth rate (CAGR) of 8.8%.
Historical market expansion has been driven by the growing use of conventional bioconjugation reagents, increased research activity at academic institutions, and broader adoption across pharmaceutical, biotechnology, and diagnostic organizations. These reagents play an important role in drug discovery, biomarker analysis, molecular imaging, therapeutic development, and laboratory research.
The bioconjugation reagents market is forecast to reach $3.87 billion by 2030, expanding at a CAGR of 9%. Growth during the forecast period is expected to be supported by rising demand for antibody-drug conjugates, greater adoption of click chemistry and covalent conjugation techniques, and increased focus on precision medicine. The development of bioconjugation kits for oligonucleotide, protein, and enzyme research is also expected to create new opportunities for reagent manufacturers and life sciences suppliers.
Artificial intelligence-driven reagent design and analytical technologies are anticipated to improve bioconjugation workflows by supporting greater precision, efficiency, and reproducibility. Key bioconjugation reagents market trends include the expanding use of click chemistry, fluorescent labeling and biotinylation reagents, covalent conjugation kits, and advanced solutions for high-precision molecular imaging and diagnostics. Demand for customizable technologies that support multiplexed analysis is also increasing across research and clinical laboratory environments.
Growth in personalized medicine remains a major market driver. Advances in genomic technologies, biomarker analysis, and molecular diagnostics are enabling healthcare providers and drug developers to select therapies more closely aligned with individual genetic and molecular profiles. Bioconjugation reagents support this shift by facilitating the precise attachment of drugs, imaging agents, and biomarkers to selected molecules, strengthening targeted therapeutic and diagnostic development.
Personalized treatment approvals also illustrate the continued expansion of this field. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, compared with six in 2022. These approvals included seven cancer drugs and three treatments for other diseases and conditions. Continued progress in personalized therapeutics is expected to increase demand for reliable bioconjugation technologies across preclinical research, clinical development, and commercial manufacturing.
Product innovation is strengthening the competitive landscape, particularly in antibody-dye conjugation. In January 2025, Bio-Rad Laboratories launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The products use SpyTag and SpyCatcher chemistry to covalently connect StarBright Blue and StarBright Violet dyes to a broad range of antibodies. They are designed to minimize antibody loss, accelerate conjugation, and support customized high-plex panels for flow cytometry and multiplexed fluorescent western blot applications.
Such product developments reflect growing demand for flexible reagent systems that maintain consistent fluorescence performance while supporting diverse antibody selections. High-efficiency conjugation kits can help researchers streamline experimental design, improve multiplex integration, and adapt assays for increasingly complex protein detection requirements. Innovation in fluorescent labeling, antibody conjugation, and high-throughput workflows is expected to remain an important source of bioconjugation reagents market growth.
Strategic acquisitions are also reshaping the market. In December 2023, Danaher Corporation acquired Abcam plc for $5.7 billion. The transaction expanded Danaher's life sciences portfolio and strengthened its capabilities in research tools and consumables used in drug discovery, diagnostics, and biological research. Abcam's portfolio includes bioconjugation reagents, validated antibodies, assays, and supporting research products for life sciences and clinical applications.
North America was the largest region in the bioconjugation reagents market in 2025, supported by its established pharmaceutical and biotechnology sectors, significant research investment, and strong presence in advanced diagnostics and drug development. Asia-Pacific is expected to be the fastest-growing region during the forecast period as life sciences research, biopharmaceutical manufacturing, and healthcare infrastructure expand. The market covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries analyzed include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Product: Crosslinkers and Coupling Agents; Activated Esters; Thiol-Reactive Reagents; Amine-Reactive Reagents; Click Chemistry Reagents; Labeling Reagents and Linkers; Conjugation Kits; Covalent Conjugation; Click Chemistry-Based
2) By Chemistry Type: Amine-Based Chemistry; Sulfhydryl-Based Chemistry; Carboxyl-Based Chemistry; Azide-Alkyne Chemistry; Photoreactive Chemistry
3) By Sales Channel: Direct Sales; Distributors and Wholesalers; Online Platforms and Ecommerce; Specialty Retailers
4) By Application: Drug Development; Antibody Drug Conjugates; Diagnostics; Molecular Imaging; Proteomics Research; Genomics Research
5) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Crosslinkers and Coupling Agents: Homobifunctional Crosslinkers; Heterobifunctional Crosslinkers; Zero Length Crosslinkers; Cleavable Crosslinkers; Non Cleavable Crosslinkers
2) By Activated Esters: N Hydroxysuccinimide Esters; Sulfo N Hydroxysuccinimide Esters; Tetrafluorophenyl Esters; Pentafluorophenyl Esters
3) By Thiol-Reactive Reagents: Maleimide Reagents; Iodoacetyl Reagents; Pyridyl Disulfide Reagents; Bromoacetyl Reagents
4) By Amine-Reactive Reagents: Isothiocyanate Reagents; Succinimidyl Ester Reagents; Carbodiimide Reagents; Imidoester Reagents
5) By Click Chemistry Reagents: Azide Reagents; Alkyne Reagents; Strained Alkyne Reagents; Tetrazine Reagents
6) By Labeling Reagents and Linkers: Fluorescent Labeling Reagents; Biotinylation Reagents; Enzyme Labeling Reagents; Polyethylene Glycol Linkers
7) By Conjugation Kits: Antibody Conjugation Kits; Protein Conjugation Kits; Oligonucleotide Conjugation Kits; Enzyme Conjugation Kits
8) By Covalent Conjugation: Amide Bond Formation; Thioether Bond Formation; Disulfide Bond Formation; Hydrazone Bond Formation
9) By Click Chemistry-Based: Copper Catalyzed Azide Alkyne Cycloaddition; Strain Promoted Azide Alkyne Cycloaddition; Inverse Electron Demand Diels Alder Reaction
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment